Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.36 per share for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2015-03-16
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $1.57.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $2.36, a 39.64% increase from fiscal 2013.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was $1.69, a 23.53% decline from fiscal 2012.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2012 was $2.21, a 102.75% increase from fiscal 2011.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2011 was $1.09.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $2.36 10-K · filed 2015-03-16 | ||||
| 2013-12-31 | $1.69 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | $1.57 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | $1.57 10-Q · filed 2013-08-14 | ||||
| 2013-03-31 | $1.57 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | $2.21 10-K · filed 2015-03-16 | $2.15 10-K · filed 2013-04-16 | |||
| 2012-09-30 | $2.20 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $2.25 10-Q/A · filed 2012-09-11 | ||||
| 2011-12-31 | $1.09 10-K · filed 2013-04-16 | $1.26 10-Q/A · filed 2012-09-11 | |||
| 2011-09-30 | $1.26 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | $1.34 10-Q/A · filed 2012-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |